Literature DB >> 19801648

Affinities between the binding partners of the HIV-1 integrase dimer-lens epithelium-derived growth factor (IN dimer-LEDGF) complex.

Manuel Tsiang1, Gregg S Jones, Magdeleine Hung, Susmith Mukund, Bin Han, Xiaohong Liu, Kerim Babaoglu, Eric Lansdon, Xiaowu Chen, Jacob Todd, Terrence Cai, Nikos Pagratis, Roman Sakowicz, Romas Geleziunas.   

Abstract

The interaction between lens epithelium-derived growth factor/transcriptional co-activator p75 (LEDGF) and human immunodeficiency virus type 1 (HIV-1) integrase (IN) is essential for HIV-1 replication. Homogeneous time-resolved fluorescence resonance energy transfer assays were developed to characterize HIV-1 integrase dimerization and the interaction between LEDGF and IN dimers. Using these assays in an equilibrium end point dose-response format with mathematical modeling, we determined the dissociation constants of IN dimers (K(dimer) = 67.8 pm) and of LEDGF from IN dimers (K(d) = 10.9 nm). When used in a kinetic format, the assays allowed the determination of the on- and off-rate constants for these same interactions. Integrase dimerization had a k(on) of 0.1247 nm(-1) x min(-1) and a k(off) of 0.0080 min(-1) resulting in a K(dimer) of 64.5 pm. LEDGF binding to IN dimers had a k(on) of 0.0285 nm(-1).min(-1) and a k(off) of 0.2340 min(-1) resulting in a K(d) of 8.2 nm. These binding assays can also be used in an equilibrium end point competition format. In this format, the IN catalytic core domain produced a K(i) of 15.2 nm while competing for integrase dimerization, confirming the very tight interaction of IN with itself. In the same format, LEDGF produced a K(i) value of 35 nm when competing for LEDGF binding to IN dimers. In summary, this study describes a methodology combining homogeneous time-resolved fluorescence resonance energy transfer and mathematical modeling to derive the affinities between IN monomers and between LEDGF and IN dimers. This study revealed the significantly tighter nature of the IN-IN dimer compared with the IN-LEDGF interaction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19801648      PMCID: PMC2785201          DOI: 10.1074/jbc.M109.040121

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75.

Authors:  Peter Cherepanov; Zhen-Yu J Sun; Shaila Rahman; Goedele Maertens; Gerhard Wagner; Alan Engelman
Journal:  Nat Struct Mol Biol       Date:  2005-05-15       Impact factor: 15.369

2.  Characterization of the dimerization process of HIV-1 reverse transcriptase heterodimer using intrinsic protein fluorescence.

Authors:  G Divita; T Restle; R S Goody
Journal:  FEBS Lett       Date:  1993-06-14       Impact factor: 4.124

3.  Analysis by surface plasmon resonance of the influence of valence on the ligand binding affinity and kinetics of an anti-carbohydrate antibody.

Authors:  C R MacKenzie; T Hirama; S J Deng; D R Bundle; S A Narang; N M Young
Journal:  J Biol Chem       Date:  1996-01-19       Impact factor: 5.157

4.  Measuring protein-protein interactions inside living cells using single color fluorescence correlation spectroscopy. Application to human immunodeficiency virus type 1 integrase and LEDGF/p75.

Authors:  Goedele Maertens; Jo Vercammen; Zeger Debyser; Yves Engelborghs
Journal:  FASEB J       Date:  2005-03-23       Impact factor: 5.191

5.  Lens epithelium-derived growth factor/p75 prevents proteasomal degradation of HIV-1 integrase.

Authors:  Manuel Llano; Sharon Delgado; Maria Vanegas; Eric M Poeschla
Journal:  J Biol Chem       Date:  2004-10-08       Impact factor: 5.157

6.  Identification of an evolutionarily conserved domain in human lens epithelium-derived growth factor/transcriptional co-activator p75 (LEDGF/p75) that binds HIV-1 integrase.

Authors:  Peter Cherepanov; Eric Devroe; Pamela A Silver; Alan Engelman
Journal:  J Biol Chem       Date:  2004-09-14       Impact factor: 5.157

7.  A soluble active mutant of HIV-1 integrase: involvement of both the core and carboxyl-terminal domains in multimerization.

Authors:  T M Jenkins; A Engelman; R Ghirlando; R Craigie
Journal:  J Biol Chem       Date:  1996-03-29       Impact factor: 5.157

8.  Dimerization of the TATA binding protein.

Authors:  R A Coleman; A K Taggart; L R Benjamin; B F Pugh
Journal:  J Biol Chem       Date:  1995-06-09       Impact factor: 5.157

9.  Class II integrase mutants with changes in putative nuclear localization signals are primarily blocked at a postnuclear entry step of human immunodeficiency virus type 1 replication.

Authors:  Richard Lu; Ana Limón; Eric Devroe; Pamela A Silver; Peter Cherepanov; Alan Engelman
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

10.  Structural basis for functional tetramerization of lentiviral integrase.

Authors:  Stephen Hare; Francesca Di Nunzio; Alfred Labeja; Jimin Wang; Alan Engelman; Peter Cherepanov
Journal:  PLoS Pathog       Date:  2009-07-17       Impact factor: 6.823

View more
  22 in total

1.  Multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors.

Authors:  Jacques J Kessl; Nivedita Jena; Yasuhiro Koh; Humeyra Taskent-Sezgin; Alison Slaughter; Lei Feng; Suresh de Silva; Li Wu; Stuart F J Le Grice; Alan Engelman; James R Fuchs; Mamuka Kvaratskhelia
Journal:  J Biol Chem       Date:  2012-03-21       Impact factor: 5.157

2.  Correlation of recombinant integrase activity and functional preintegration complex formation during acute infection by replication-defective integrase mutant human immunodeficiency virus.

Authors:  Xiang Li; Yasuhiro Koh; Alan Engelman
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

3.  New class of HIV-1 integrase (IN) inhibitors with a dual mode of action.

Authors:  Manuel Tsiang; Gregg S Jones; Anita Niedziela-Majka; Elaine Kan; Eric B Lansdon; Wayne Huang; Magdeleine Hung; Dharmaraj Samuel; Nikolai Novikov; Yili Xu; Michael Mitchell; Hongyan Guo; Kerim Babaoglu; Xiaohong Liu; Romas Geleziunas; Roman Sakowicz
Journal:  J Biol Chem       Date:  2012-04-25       Impact factor: 5.157

4.  Slow, reversible, coupled folding and binding of the spectrin tetramerization domain.

Authors:  S L Shammas; J M Rogers; S A Hill; J Clarke
Journal:  Biophys J       Date:  2012-11-20       Impact factor: 4.033

Review 5.  HIV-1 integrase multimerization as a therapeutic target.

Authors:  Lei Feng; Ross C Larue; Alison Slaughter; Jacques J Kessl; Mamuka Kvaratskhelia
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

6.  Free Energy-Based Computational Methods for the Study of Protein-Peptide Binding Equilibria.

Authors:  Emilio Gallicchio
Journal:  Methods Mol Biol       Date:  2022

7.  Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.

Authors:  Michael E Abram; Rebecca M Hluhanich; Derrick D Goodman; Kristen N Andreatta; Nicolas A Margot; Linda Ye; Anita Niedziela-Majka; Tiffany L Barnes; Nikolai Novikov; Xiaowu Chen; Evguenia S Svarovskaia; Damian J McColl; Kirsten L White; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

Review 8.  Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity.

Authors:  Matthew C Smith; Jason E Gestwicki
Journal:  Expert Rev Mol Med       Date:  2012-07-26       Impact factor: 5.600

9.  Interrogating HIV integrase for compounds that bind--a SAMPL challenge.

Authors:  Thomas S Peat; Olan Dolezal; Janet Newman; David Mobley; John J Deadman
Journal:  J Comput Aided Mol Des       Date:  2014-02-16       Impact factor: 3.686

10.  Allosteric HIV-1 integrase inhibitors promote aberrant protein multimerization by directly mediating inter-subunit interactions: Structural and thermodynamic modeling studies.

Authors:  Nanjie Deng; Ashley Hoyte; Yara E Mansour; Mosaad S Mohamed; James R Fuchs; Alan N Engelman; Mamuka Kvaratskhelia; Ronald Levy
Journal:  Protein Sci       Date:  2016-08-17       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.